1. Introduction {#sec1}
===============

*Staphylococcus aureus*(*S. aureus*) is one of the most important pathogens in both hospitals and the community and can cause numerous syndromes in humans, such as furuncle, carbuncle, abscess, pneumonia, meningitis, bacterial arthritis, myocarditis, endocarditis, osteomyelitis, and septicemia \[[@B1]--[@B3]\]. Methicillin-resistant*Staphylococcus aureus*(MRSA) is a significant problem in hospitals and communities worldwide, and awareness of MRSA in animals and reports of its zoonotic spread have increased in recent years \[[@B3], [@B4]\]. The increasing prevalence of methicillin-resistant*Staphylococcus aureus* (MRSA) has led to widespread, increased use of vancomycin \[[@B5], [@B6]\]. Subsequently, numerous reports of elevated minimum inhibitory concentrations (MIC) to vancomycin among MRSA isolates have surfaced, concomitant with increased global vancomycin exposure to MRSA \[[@B7], [@B8]\]. Greater than 60% of*S. aureus*isolates are now resistant to methicillin (oxacillin), and some strains have developed resistance to more than 20 different antimicrobial agents; new agents are therefore needed for the treatment of*S. aureus*\[[@B9], [@B10]\]. Plant medicines are used on a worldwide scale to prevent and treat infectious diseases. They are of great demand both in the developed and developing countries for the primary health care needs due to their wide biological and medicinal activities, higher safety margin and lesser costs \[[@B11], [@B12]\]. Plants are rich in a wide variety of secondary metabolites such as tannins, alkaloids, terpenoids, and flavonoids having been found*in vitro*since they have antimicrobial properties and may serve as an alternative, effective, cheap, and safe antimicrobial for the treatment of microbial infections \[[@B12]--[@B15]\]. At the same time, because of the difficulty in developing chemical synthetic drugs and because of their side effects, scientists are making more efforts to search for new drugs from plant resources to combat clinical multidrug-resistant microbial infections \[[@B11], [@B12], [@B16]\].

The main components of*S. miltiorrhiza*can be divided into two groups: hydrophilic compounds such as salvianolic acids and lipophilic chemicals, including diterpenoid and tanshinones \[[@B17]\]. The second group of components, labeled as tanshinone I, tanshinone II, and cryptotanshinone, are the major bioactive constituents and have various kinds of pharmacological effects including antibacterial, antioxidant, and antitumor activities and prevention of angina pectoris and myocardial infarction \[[@B18]--[@B20]\]. The cryptotanshinone (CT) exhibits antimicrobial activity against a broad range of Gram-positive bacteria, including*S. aureus*, and Gram-negative bacteria as well as other microorganisms \[[@B18], [@B21]\]. The hexane and chloroform fractions of*S. miltiorrhiza*evidenced profound antimicrobial activity and inhibited resistant gene expression against*Staphylococcus aureus*and MRSA (methicillin-resistant*Staphylococcus aureus*) \[[@B21], [@B22]\].

In this study, the antimicrobial activities of cryptotanshinone (CT) against methicillin and vancomycin-resistant*Staphylococcus aureus*isolated in a clinic were assessed using broth microdilution method and the checkerboard and time-kill methods for synergistic effect of the combination with antibiotics.

2. Materials and Methods {#sec2}
========================

2.1. Plant Extraction and Isolation {#sec2.1}
-----------------------------------

The air-dried roots (2.0 kg) of*S. miltiorrhiza*were crushed and extracted with MeOH (8 L × 3) at room temperature. The MeOH extracts (210 g) were evaporated and suspended in distilled water and partitioned sequentially with CH~2~Cl~2~, EtOAc, and*n*-BuOH. The CH~2~Cl~2~ soluble fraction was concentrated*in vacuo,*and its crude extract (28 g) was subjected to silica gel column chromatography using a CHCl~3~-MeOH gradient solvent system to provide ten fractions (A1--A10). Fraction A4 was further subjected to silica gel column chromatography with a CHCl~3~-MeOH (10 : 1) to yield five fractions (B1--B5). Fraction B3 was purified on recycling prep-HPLC (JAIGEL GS column and 220 nm) eluted with MeOH (4.0 mL/min) to yield cryptotanshinone (98 mg). The structure of cryptotanshinone was identified by comparing its spectral data with those published \[[@B23], [@B24]\].

2.2. Preparation of Bacterial Strains {#sec2.2}
-------------------------------------

16 isolates of methicillin-resistant*Staphylococcus aureus*, 2 isolates of methicillin-sensitive*S. aureus*(MSSA), and 2 isolates of vancomycin-resistant*S. aureus* (VRSA) were purchased from the Culture Collection of Antimicrobial Resistant Microbes (CCARM); standard strains of methicillin-sensitive*S. aureus*(MSSA) ATCC 25923 and methicillin-resistant*S. aureus*(MRSA) ATCC 33591 were used as well ([Table 1](#tab1){ref-type="table"}). Antibiotic susceptibility was determined in testing the inhibition zones (inoculums 0.5 McFarland suspension, 1.5 × 10^8^ CFU/mL) and MIC/MBC (inoculums 5 × 10^5^ CFU/mL) for strains, measured as described in the National Committee for Clinical Laboratory Standards (NCCLS, 1999). Briefly, the growth of bacteria was examined at 37°C in 0.95 mL of BHI broth containing various concentrations of CT. These tubes were inoculated with 5 × 10^5^ colony-forming units (CFU)/mL of an overnight culture grown in BHI broth and incubated at 37°C. After 24 h of incubation, the optical density (OD) was measured spectrophotometrically at 550 nm. Three replicates were measured for each concentration of tested drugs.

2.3. Minimum Inhibitory Concentration/Minimum Bactericidal Concentration Assay {#sec2.3}
------------------------------------------------------------------------------

The antimicrobial activities of CT against clinical isolates MRSA 16, MSSA 2, VRSA 2, and reference strains were determined*via* the broth dilution method \[[@B25]\]. The minimum inhibitory concentration (MIC) was recorded as the lowest concentration of test samples resulting in the complete inhibition of visible growth. For clinical strains, MIC~50~s and MIC~90~s, defined as MICs at which 50 and 90%, respectively, of the isolates were inhibited, were determined. The minimum bactericidal concentration (MBC) was determined based on the lowest concentration of the extracts required to kill 99.9% of bacteria from the initial inoculum as determined by plating on agar.

2.4. Checkerboard Dilution Test {#sec2.4}
-------------------------------

The synergistic combinations were investigated in the preliminary checkerboard method performed using the MRSA, MSSA, and VRSA of clinical isolate strains via MIC and MBC determination \[[@B26]\]. The fractional inhibitory concentration index (FICI) and fractional bactericidal concentration index (FBCI) are the sum of the FICs and FBCs of each of the drugs, which were defined as the MIC and MBC of each drug when used in combination divided by the MIC and MBC of each drug when used alone. The FIC and FBC index was calculated as follows: FIC = (MIC of drug A in combination/MIC of drug A alone) + (MIC of drug B in combination/MIC of drug B alone) and FBC = (MBC of drug A in combination/MBC of drug A alone) + (MBC of drug B in combination/MBC of drug B alone). FIC and FBC indices were interpreted as follows: the FIC index was interpreted as follows: synergy, \<0.5; partial synergy, 0.5--0.75; additive effect, 0.76--1.0; indifference, \>1.0--4.0; and antagonism, \>4.0 \[[@B26]\].

2.5. Time-Kill Curves {#sec2.5}
---------------------

The bactericidal activities of the drugs evaluated in this study were also evaluated using time-kill curves constructed using the isolated and reference strains. Cultures with an initial cell density of 1--5 × 10^6^ CFU/mL were exposed to the MIC of CT alone or CT (1/2 MIC) plus oxacillin or ampicillin or vancomycin (1/2 MIC). Viable counts were conducted at 0, 0.5, 1, 2, 3, 4, 5, 6, 12, and 24 h by plating aliquots of the samples on agar and subsequent incubation for 24 hours at 37°C. All experiments were repeated several times and colony counts were conducted in duplicate, after which the means were determined.

3. Results and Discussion {#sec3}
=========================

Many researchers are studying natural products that could be used as antibiotics against MRSA and are employing novel dosing regimens and antimicrobials that would be advantageous for combating the therapeutic problems associated with*S. aureus*\[[@B10], [@B13], [@B14], [@B16], [@B27]\]. The main bioactive constituents of*S. miltiorrhiza*include water-soluble phenolic acids and lipophilic diterpenoid tanshinones \[[@B28]--[@B30]\]. Cryptotanshinone was isolated from dried*S. miltiorrhiza*roots and identified via comparison of their spectral data with the data reported in the literature \[[@B23], [@B24]\]. ^l^H-NMR (CDCl~3~) *δ* 7.64 (1H, d,*J* = 8.0 Hz), 7.48 (1H, d,*J* = 8.0 Hz), 4.86 (1H, t,*J* = 9.2 Hz), 4.36 (1H, dd,*J* = 6.0 and 6.0 Hz), 3.60 (1H, m), 3.21 (2H, br t), 1.69 (4H, m), 1.36 (3H, d,*J* = 6.4 Hz), 1.31 (6H, s). ^13^C-NMR (CDCl~3~) *δ* 29.67 (C-1), 19.08 (C-2), 37.82 (C-3), 34.86 (C-4), 143.70 (C-5), 132.56 (C-6), 122.50 (C-7), 128.42 (C-8), 126.27 (C-9), 152.37 (C-10), 184.27 (C-11), 175.72 (C-12), 118.30 (C-13), 170.75 (C-14), 81.46 (C-15), 34.62 (C-16), 18.85 (C-17), 31.94 (C-18), and 31.89 (C-19). Among the lipophilic diterpenoid tanshinones, cryptotanshinone, dihydrotanshinone I, tanshinone IIA, and tanshinone I exhibited strong antimicrobial activity against (*Agrobacterium tumefaciens*ATCC 11158,*Escherichia coli*ATCC 29425,*Pseudomonas lachrymans*ATCC 11921,*Ralstonia solanacearum*ATCC 11696, and*Xanthomonas vesicatoria*ATCC 11633) and three Gram-positive bacteria (*Bacillus subtilis*ATCC 11562,*Staphylococcus aureus*ATCC 6538, and*Staphylococcus haemolyticus*ATCC 29970) \[[@B18]\]. Our results of the antibacterial activity showed that the CT exhibited inhibitory activities against isolates MSSA, MRSA, VRSA, and reference stains. The MICs and MBCs values of CT and antibiotics, ampicillin, oxacillin, and vancomycin against MSSA ATCC 25923 and MRSA ATCC 33591 and isolates MSSA 1-2, MRSA 1--16, and VRSA 1-2 are shown in [Table 1](#tab1){ref-type="table"}. The MICs and MBCs values of CT against isolates MSSA 1-2 were in the range of 16 and 32 *μ*g/mL and 64 and 128 *μ*g/mL, isolates MRSA 1--16 in the range of 4--64 *μ*g/mL and 8--128 *μ*g/mL, isolates VRSA 1-2 in the range of 2 and 4 *μ*g/mL and 4 and 16 *μ*g/mL, and reference stains in range of 4 and 64 *μ*g/mL and 16 and 256 *μ*g/mL, respectively. The MICs/MBCs for ampicillin were determined to be either 8/16 or 1024/2048 *μ*g/mL; for oxacillin, either 0.25/1 or 512/2048 *μ*g/mL; for vancomycin, either 0.5/2 or 32/64 *μ*g/mL against reference strains and MSSA 1-2, MRSA 1--16, and VRSA 1-2 isolates. The MIC~50~ and MIC~90~ values of CT for reference strains were 0.5 and 4 *μ*g/mL and 4 and 64 *μ*g/mL, while for MSSA 1-2 and VRSA 1-2 isolates were 0.5--8 *μ*g/mL and 2--32 *μ*g/mL, and for MRSA 1--16 isolates were 0.5--8 *μ*g/mL and 4--64 *μ*g/mL, respectively ([Table 1](#tab1){ref-type="table"}).

Evaluation of*in vivo* effectiveness of the antimicrobial combinations is necessary to generate data that can be extrapolated to the clinical situation as well as predicting relevant concentration of optimal dosing regimens for both agents of the combinations \[[@B31], [@B32]\]. Combination antibiotic therapy has been studied to promote the effective use of antibiotics in increasing*in vivo*activity of antibiotics, in preventing the spread of drug-resistant strains, and in minimizing toxicity \[[@B32], [@B33]\]. The combination of oxacillin and CT resulted in a reduction in the MICs/MBCs for isolates VRSA 1-2 and MSSA 1-2, with the MICs/MBCs of 2/16 or 8/128 *μ*g/mL, for oxacillin becoming 0.125/0.125--0.25 *μ*g/mL and reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤0.5 ([Table 2](#tab2){ref-type="table"}). The combination of oxacillin and CT resulted in a reduction against isolates MRSA 1--16, with the MICs/MBCs values of 0.5--16/2--32 *μ*g/mL, for oxacillin becoming 1--128/4--256 *μ*g/mL and reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤0.5 except MRSA 4 and 16 of additive (FICI ≥ 0.5) and MRSA 1, 7, and 15 of additive (FBCI ≥ 0.5). The combination of ampicillin and CT resulted in a reduction in the MICs/MBCs for isolates VRSA 1-2 and MSSA 1-2, with the MICs/MBCs of 0.5/1 or 2/4 *μ*g/mL and 4/8 or 8/16, for ampicillin becoming 32/128 or 64/256 *μ*g/mL and 16/64 or 32/128 *μ*g/mL and reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤0.5 and in most of MRSA testedwere reduced by ≥4-fold evidencing a synergistic effect as defined by a FICI and FBCI of ≤0.5 except MRSA 6, 12, and 15 (FICI ≥ 0.5) and MRSA 6, 11, and 13 (FBCI ≥ 0.5), respectively ([Table 3](#tab3){ref-type="table"}). The combination of vancomycin and CT resulted in a reduction against isolates MRSA 1--16, with the MICs/MBCs values of 1--16/2--32 *μ*g/mL, for vancomycin becoming 0.125--0.5/0.5--2 *μ*g/mL and reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤ 0.5 except MRSA 6, 11, and 15 of additive (FICI ≥ 0.5) and MRSA 1 and 9 of additive (FBCI ≥ 0.5) and for isolates VRSA 1-2 and MSSA 1-2, with the MICs/MBCs of 0.5/1 or 1/4 *μ*g/mL and 4/8 or 16/16, for vancomycin becoming 4/8 or 8/16 *μ*g/mL and 0.25/2 or 0.25/1 *μ*g/mL and reduced by ≥4-fold, evidencing a synergistic effect as defined by a FICI and FBCI of ≤0.5 except MSSA 1 and 2 of additive (FBCI ≥ 0.5) ([Table 4](#tab4){ref-type="table"}).

The effects of CT administered in combination with oxacillin and/or ampicillin and/or vancomycin against standard (MSSA and MRSA) and clinical isolates of MSSA (1, 2), VRSA (1,2), and MRSA (MRSA 1--16) were confirmed by time-kill curve experiments (Figures [1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, [7](#fig7){ref-type="fig"}, and [8](#fig8){ref-type="fig"}). Cultures of each strain of bacteria with a cell density of 10^6^ CFU/mL were exposed to the MIC of CT and antibiotics alone or CT (1/2 MIC) with oxacillin (1/2 MIC), ampicillin (1/2 MIC), or vancomycin (1/2 MIC). We observed that 30 minutes of CT treatment with ampicillin, oxacillin, or vancomycin resulted in an increased rate of killing as compared to that observed with CT (MIC) alone. A profound bactericidal effect was exerted when a combination of drugs was utilized. The growth of the tested bacteria was completely attenuated after 2--5 h of treatment with the 1/2 MIC of CT, regardless of whether it was administered alone or with oxacillin (1/2 MIC), ampicillin (1/2 MIC), or vancomycin (1/2 MIC) (Figures [1](#fig1){ref-type="fig"}--[8](#fig8){ref-type="fig"}).

It has been reported that some plant-derived compounds can improve the*in vitro* activity of some cell-wall inhibiting antibiotics by directly attacking the same target site, that is, peptidoglycan \[[@B7], [@B9], [@B34]\]. CT exhibits antimicrobial activity against a broad range of Gram-positive bacteria, including*S. aureus*, and Gram-negative bacteria as well as other microorganisms \[[@B21], [@B22]\]. Despite the pharmacological activities, potential risks regarding combination use of*S. miltiorrhiza* and drugs have been observed \[[@B28], [@B35], [@B36]\]. Scientific findings concluded*S. miltiorrhiza*fraction, and its components (cryptotanshinone and dihydrotanshinone I) showed antibacterial activity against a broad range of bacteria, including the broad range of Gram-positive bacteria and Gram-negative bacteria, and superoxide radicals are considered important in the antibacterial actions of the agents \[[@B18]\]. The Gram-positive bacteria-specific properties of CT are caused by the inhibition of RNA and protein synthesis, rather than by attacking the bacterial membrane \[[@B21], [@B22]\].

In conclusion, CT of*S. miltiorrhiza*is expected to be recognized as natural sources for the development of new functional drugs against multiresistant*S. aureus*, MRSA and VRSA.
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![Time-kill curves of MIC or 1/2 MIC of cryptotanshinone (CT), ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with MIC~50~ of AMP or OXA, and VAN against VRSA 1 isolates and reference stains, MSSA ATCC 25923 and MRSA ATCC 33591. Bacteria were incubated with MIC of CT (●), AMP, OXA, and VAN, and 1/2 MIC of CT + 1/2 MIC of AMP (○), 1/2 MIC of CT + 1/2 MIC of OXA (*▼*), and 1/2 MIC of CT + 1/2 MIC of VAN (*∇*) over time. CFU: colony-forming units.](ECAM2014-450572.001){#fig1}

![Time-kill curves of MIC or 1/2 MIC of cryptotanshinone (CT), ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with 1/2 MIC of AMP or OXA, and VAN against VRSA 2, MSSA 1, and MSSA 2 isolates. Bacteria were incubated with MIC of CT (●), AMP, OXA, and VAN, and 1/2 MIC of CT + 1/2 MIC of AMP (○), 1/2 MIC of CT + 1/2 MIC of OXA (*▼*), and 1/2 MIC of CT + 1/2 MIC of VAN (*∇*) over time. CFU: colony-forming units.](ECAM2014-450572.002){#fig2}

![Time-kill curves of MIC or 1/2 MIC of cryptotanshinone (CT), ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with 1/2 MIC of AMP or OXA, and VAN against MRSA 1, 2, and 3 isolates. Bacteria were incubated with MIC of CT (●), AMP, OXA, and VAN, and 1/2 MIC of CT + 1/2 MIC of AMP (○), 1/2 MIC of CT + 1/2 MIC of OXA (*▼*), and 1/2 MIC of CT + 1/2 MIC of VAN (*∇*) over time. CFU: colony-forming units.](ECAM2014-450572.003){#fig3}

![Time-kill curves of MIC or 1/2 MIC of cryptotanshinone (CT), ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with 1/2 MIC of AMP or OXA, and VAN against MRSA 4, 5, and 6 isolates. Bacteria were incubated with MIC of CT (●), AMP (○), OXA (*▼*), and VAN (*∇*), and 1/2 MIC of CT + 1/2 MIC of AMP (●), 1/2 MIC of CT + 1/2 MIC of OXA (○), and 1/2 MIC of CT + 1/2 MIC of VAN (*▼*) over time. CFU: colony-forming units.](ECAM2014-450572.004){#fig4}

![Time-kill curves of MIC or 1/2 MIC of cryptotanshinone (CT), ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with 1/2 MIC of AMP or OXA, and VAN against MRSA 7, 8, and 9 isolates. Bacteria were incubated with MIC of CT (●), AMP (○), OXA (*▼*), and VAN (*∇*), and 1/2 MIC of CT + 1/2 MIC of AMP (●), 1/2 MIC of CT + 1/2 MIC of OXA (○), and 1/2 MIC of CT + 1/2 MIC of VAN (*▼*) over time. CFU: colony-forming units.](ECAM2014-450572.005){#fig5}

![Time-kill curves of MIC or 1/2 MIC of cryptotanshinone (CT), ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with 1/2 MIC of AMP or OXA, and VAN against MRSA 10, 11, and 12 isolates. Bacteria were incubated with MIC of CT (●), AMP (○), OXA (*▼*), and VAN (*∇*), and 1/2 MIC of CT + 1/2 MIC of AMP (●), 1/2 MIC of CT + 1/2 MIC of OXA (○), and 1/2 MIC of CT + 1/2 MIC of VAN (*▼*) over time. CFU: colony-forming units.](ECAM2014-450572.006){#fig6}

![Time-kill curves of MIC or 1/2 MIC of cryptotanshinone (CT), ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with 1/2 MIC of AMP or OXA, and VAN against MRSA 13, 14, and 15 isolates. Bacteria were incubated with MIC of CT (●), AMP (○), OXA (*▼*), and VAN (*∇*), and 1/2 MIC of CT + 1/2 MIC of AMP (●), 1/2 MIC of CT + 1/2 MIC of OXA (○), and 1/2 MIC of CT + 1/2 MIC of VAN (*▼*) over time. CFU: colony-forming units.](ECAM2014-450572.007){#fig7}

![Time-kill curves of MIC or 1/2 MIC of cryptotanshinone (CT), ampicillin (AMP), oxacillin (OXA), and vancomycin (VAN) alone and its combination with 1/2 MIC of AMP or OXA, and VAN against MRSA 16 isolate. Bacteria were incubated with MIC of CT (●), AMP (○), OXA (*▼*), and VAN (*∇*), and 1/2 MIC of CT + 1/2 MIC of AMP (●), 1/2 MIC of CT + 1/2 MIC of OXA (○), and 1/2 MIC of CT + 1/2 MIC of VAN (*▼*) over time. CFU: colony-forming units.](ECAM2014-450572.008){#fig8}

###### 

Antibacterial activity of cryptotanshinone and antibiotics in isolated MRSA, VRSA, MSSA, and some of reference bacteria.

  Samples              Cryptotanshinone (*μ*g/mL)   Ampicillin   Oxacillin   Vancomycin              
  -------------------- ---------------------------- ------------ ----------- ------------ ---------- -------
  MSSA ATCC 25923^1^   4                            64           64/256      8/16         0.25/1     0.5/2
  MRSA ATCC 33591^2^   0.5                          4            4/16        512/2048     8/16       1/4
  VRSA 3A063^3^        0.5                          2            2/4         512/2048     512/1024   16/32
  VRSA 3A066^4^        1                            4            4/16        128/256      512/1024   32/64
  MSSA 1^5^            2                            16           16/64       1024/2048    0.5/1      1/4
  MSSA 2^6^            8                            32           32/128      256/512      1/2        1/2
  MRSA 1               2                            16           16/32       128/256      128/256    1/2
  MRSA 2               8                            64           64/128      256/256      8/32       2/4
  MRSA 3               1                            4            4/16        128/512      128/512    2/4
  MRSA 4               0.5                          4            4/8         128/256      512/2048   1/2
  MRSA 5               2                            64           64/128      128/512      512/1024   1/2
  MRSA 6               0.5                          4            4/16        64/128       64/256     1/2
  MRSA 7               2                            8            8/16        128/256      512/1024   1/4
  MRSA 8               4                            32           32/64       256/256      512/2048   1/4
  MRSA 9               2                            8            8/16        64/128       512/1024   1/2
  MRSA 10              2                            16           16/64       128/256      512/1024   1/2
  MRSA 11              4                            8            8/32        64/128       64/128     1/2
  MRSA 12              1                            4            4/8         128/256      128/256    1/4
  MRSA 13              4                            32           32/128      128/256      32/128     1/2
  MRSA 14              0.5                          8            8/16        64/128       8/16       1/4
  MRSA 15              0.5                          4            4/16        64/128       128/256    1/4
  MRSA 16              2                            8            8/16        128/512      128/512    1/2

  ^1^MSSA (ATCC 25923): reference strain methicillin-sensitive *Staphylococcus aureus.*

^2^MRSA (ATCC 33591): reference strain methicillin-resistant *Staphylococcus aureus.*

^3^VRSA 3A063: vancomycin-resistant *Staphylococcus aureus* isolated clinically.

^4^VRSA 3A066: vancomycin-resistant *Staphylococcus aureus* isolated clinically.

^5^MSSA (1-2): methicillin-sensitive *Staphylococcus aureus* isolated clinically.

^6^MRSA (1--16): methicillin-resistant *Staphylococcus aureus*isolated clinically.

###### 

Synergistic effects of the cryptotanshinone with oxacillin in isolated MRSA, VRSA, MSSA, and some of reference bacteria.

  Samples              Agent              MIC/MBC (*μ*g/mL)   FIC/FBC        FICI/FBCI^2^   Outcome        
  -------------------- ------------------ ------------------- -------------- -------------- -------------- -----------------------------
  MSSA ATCC 25923^3^   Cryptotanshinone   64/256              8/32           0.125/0.125    0.375/0.375    **Synergistic/synergistic**
  Oxacillin            0.25/1             0.0625/0.25         0.25/0.25                                    
  MRSA ATCC 33591^4^   Cryptotanshinone   4/16                1/4            0.25/0.25      0.5/0.5        **Synergistic/synergistic**
  Oxacillin            8/16               2/4                 0.25/0.25                                    
  VRSA 3A063^5^        Cryptotanshinone   2/4                 0.5/2          0.25/0.5       0.375/0.375    **Synergistic/synergistic**
  Oxacillin            512/1024           64/128              0.125/0.125                                  
  VRSA 3A066^6^        Cryptotanshinone   4/16                1/4            0.25/0.25      0.375/0.5      **Synergistic/synergistic**
  Oxacillin            512/1024           64/256              0.125/0.25                                   
  MSSA 1^7^            Cryptotanshinone   16/64               2/8            0.125/0.125    0.375/0.25     **Synergistic/synergistic**
  Oxacillin            0.5/1              0.125/0.125         0.25/0.125                                   
  MSSA 2               Cryptotanshinone   32/128              16/32          0.5/0.25       0.375/0.375    **Synergistic/synergistic**
  Oxacillin            1/2                0.125/0.25          0.125/0.125                                  
  MRSA 1^8^            Cryptotanshinone   16/32               4/16           0.25/0.5       0.5/0.75       **Synergistic/additive**
  Oxacillin            128/256            32/64               0.25/0.25                                    
  MRSA 2               Cryptotanshinone   64/128              16/16          0.25/0.125     0.5/0.375      **Synergistic/synergistic**
  Oxacillin            8/32               2/8                 0.25/0.25                                    
  MRSA 3               Cryptotanshinone   4/16                0.5/4          0.125/0.25     0.375/0.375    **Synergistic/synergistic**
  Oxacillin            128/512            32/64               0.25/0.125                                   
  MRSA 4               Cryptotanshinone   4/8                 2/2            0.5/0.25       0.75/0.375     **Additive/synergistic**
  Oxacillin            512/2048           128/256             0.25/0.125                                   
  MRSA 5               Cryptotanshinone   64/128              16/32          0.25/0.25      0.375/0.5      **Synergistic/synergistic**
  Oxacillin            512/1024           64/256              0.125/0.25                                   
  MRSA 6               Cryptotanshinone   4/16                1/4            0.25/0.25      0.5/0.5        **Synergistic/synergistic**
  Oxacillin            64/256             16/64               0.25/0.25                                    
  MRSA 7               Cryptotanshinone   8/16                2/8            0.25/0.5       0.375/0.75     **Synergistic/additive**
  Oxacillin            512/1024           64/256              0.125/0.25                                   
  MRSA 8               Cryptotanshinone   32/64               8/32           0.25/0.5       0.5/0.625      **Synergistic/synergistic**
  Oxacillin            512/2048           128/256             0.25/0.125                                   
  MRSA 9               Cryptotanshinone   8/16                2/4            0.25/0.25      0.375/0.3125   **Synergistic/synergistic**
  Oxacillin            512/1024           64/64               0.125/0.0625                                 
  MRSA 10              Cryptotanshinone   16/64               2/8            0.125/0.125    0.3125/0.25    **Synergistic/synergistic**
  Oxacillin            512/1024           32/128              0.0625/0.125                                 
  MRSA 11              Cryptotanshinone   8/32                1/4            0.125/0.125    0.375/0.375    **Synergistic/synergistic**
  Oxacillin            64/128             16/64               0.25/0.5                                     
  MRSA 12              Cryptotanshinone   4/8                 1/2            0.25/0.25      0.5/0.5        **Synergistic/synergistic**
  Oxacillin            128/256            32/64               0.25/0.25                                    
  MRSA 13              Cryptotanshinone   32/128              8/32           0.25/0.25      0.5/0.375      **Synergistic/synergistic**
  Oxacillin            32/128             8/8                 0.25/0.125                                   
  MRSA 14              Cryptotanshinone   8/16                2/4            0.25/0.25      0.375/0.5      **Synergistic/synergistic**
  Oxacillin            8/16               1/4                 0.125/0.25                                   
  MRSA 15              Cryptotanshinone   4/16                1/8            0.25/0.5       0.5/0.75       **Synergistic/additive**
  Oxacillin            128/256            32/64               0.25/0.25                                    
  MRSA 16              Cryptotanshinone   8/16                2/4            0.25/0.25      0.75/0.375     **Additive/synergistic**
  Oxacillin            128/512            64/64               0.5/0.125                                    

  ^1^The MIC and MBC of cryptotanshinone with oxacillin.

^2^The FIC index.

^3^MSSA (ATCC 25923): reference strain methicillin-sensitive *Staphylococcus aureus.*

^4^MRSA (ATCC 33591): reference strain methicillin-resistant *Staphylococcus aureus.*

^5^VRSA 3A063: vancomycin-resistant *Staphylococcus aureus* isolated clinically.

^6^VRSA 3A066: vancomycin-resistant *Staphylococcus aureus* isolated clinically.

^7^MSSA (1-2): methicillin-sensitive *Staphylococcus aureus* isolated clinically.

^8^MRSA (1--16): methicillin-resistant *Staphylococcus aureus* isolated clinically.

###### 

Synergistic effects of cryptotanshinone with ampicillin in isolated MRSA, VRSA, MSSA, and some of reference bacteria.

  Samples              Agent              MIC/MBC (*μ*g/mL)   FIC/FBC      FICI/FBCI^2^   Outcome       
  -------------------- ------------------ ------------------- ------------ -------------- ------------- -----------------------------
  MSSA ATCC 25923^3^   Cryptotanshinone   64/256              16/64        0.25/0.25      0.5/0.75      **Synergistic/additive**
  Ampicillin           8/16               2/8                 0.25/0.5                                  
  MRSA ATCC 33591^4^   Cryptotanshinone   4/16                1/4          0.25/0.25      0.5/0.5       **Synergistic/synergistic**
  Ampicillin           512/2048           128/512             0.25/0.25                                 
  VRSA 3A063^5^        Cryptotanshinone   2/4                 0.5/2        0.25/0.5       0.5/0.375     **Synergistic/synergistic**
  Ampicillin           512/2048           128/256             0.25/0.125                                
  VRSA 3A066^6^        Cryptotanshinone   4/16                1/4          0.25/0.25      0.5/0.5       **Synergistic/synergistic**
  Ampicillin           128/256            32/64               0.25/0.25                                 
  MSSA 1^7^            Cryptotanshinone   16/64               4/8          0.25/0.125     0.5/0.375     **Synergistic/synergistic**
  Ampicillin           64/128             16/32               0.25/0.25                                 
  MSSA 2               Cryptotanshinone   32/128              8/16         0.25/0.125     0.5/0.375     **Synergistic/synergistic**
  Ampicillin           256/512            64/128              0.25/0.25                                 
  MRSA 1^8^            Cryptotanshinone   16/32               4/8          0.25/0.25      0.5/0.5       **Synergistic/synergistic**
  Ampicillin           128/256            32/64               0.25/0.25                                 
  MRSA 2               Cryptotanshinone   64/128              16/32        0.25/0.25      0.5/0.5       **Synergistic/synergistic**
  Ampicillin           64/256             16/64               0.25/0.25                                 
  MRSA 3               Cryptotanshinone   4/16                1/2          0.25/0.125     0.5/0.25      **Synergistic/synergistic**
  Ampicillin           128/512            32/64               0.25/0.125                                
  MRSA 4               Cryptotanshinone   4/8                 1/2          0.25/0.25      0.5/0.5       **Synergistic/synergistic**
  Ampicillin           128/256            32/64               0.25/0.25                                 
  MRSA 5               Cryptotanshinone   64/128              16/32        0.25/0.25      0.5/0.5       **Synergistic/synergistic**
  Ampicillin           256/512            64/128              0.25/0.25                                 
  MRSA 6               Cryptotanshinone   4/16                1/2          0.25/0.125     0.75/0.625    **Additive/additive**
  Ampicillin           64/128             32/64               0.5/0.5                                   
  MRSA 7               Cryptotanshinone   8/16                2/4          0.25/0.25      0.5/0.5       **Synergistic/synergistic**
  Ampicillin           128/256            32/64               0.25/0.25                                 
  MRSA 8               Cryptotanshinone   32/64               8/16         0.25/0.25      0.5/0.375     **Synergistic/synergistic**
  Ampicillin           32/64              8/8                 0.25/0.125                                
  MRSA 9               Cryptotanshinone   8/16                2/4          0.25/0.25      0.5/0.5       **Synergistic/synergistic**
  Ampicillin           64/128             16/32               0.25/0.25                                 
  MRSA 10              Cryptotanshinone   16/64               2/8          0.125/0.125    0.375/0.375   **Synergistic/synergistic**
  Ampicillin           128/256            32/64               0.25/0.25                                 
  MRSA 11              Cryptotanshinone   8/32                2/8          0.25/0.25      0.5/0.75      **Synergistic/additive**
  Ampicillin           64/128             16/64               0.25/0.5                                  
  MRSA 12              Cryptotanshinone   4/8                 1/2          0.25/0.25      0.75/0.5      **Additive/synergistic**
  Ampicillin           128/256            64/64               0.5/0.25                                  
  MRSA 13              Cryptotanshinone   32/128              8/32         0.25/0.25      0.5/0.75      **Synergistic/additive**
  Ampicillin           128/256            32/128              0.25/0.5                                  
  MRSA 14              Cryptotanshinone   8/16                2/4          0.25/0.25      0.375/0.5     **Synergistic/synergistic**
  Ampicillin           64/128             8/32                0.125/0.25                                
  MRSA 15              Cryptotanshinone   4/16                2/4          0.5/0.25       0.75/0.5      **Additive/synergistic**
  Ampicillin           64/128             16/32               0.25/0.25                                 
  MRSA 16              Cryptotanshinone   8/16                2/4          0.25/0.25      0.5/0.375     **Synergistic/synergistic**
  Ampicillin           128/512            32/64               0.25/0.125                                

  ^1^The MIC and MBC of cryptotanshinone with ampicillin.

^2^The FIC index.

^3^MSSA (ATCC 25923): reference strain methicillin-sensitive *Staphylococcus aureus.*

^4^MRSA (ATCC 33591): reference strain methicillin-resistant *Staphylococcus aureus.*

^5^VRSA 3A063: vancomycin-resistant *Staphylococcus aureus* isolated clinically.

^6^VRSA 3A066: vancomycin-resistant *Staphylococcus aureus* isolated clinically.

^7^MSSA (1-2): methicillin-sensitive *Staphylococcus aureus* isolated clinically.

^8^MRSA (1--16): methicillin-resistant *Staphylococcus aureus*isolated clinically.

###### 

Synergistic effects of cryptotanshinone with vancomycin in isolated MRSA, VRSA, MSSA, and some of reference bacteria.

  Samples              Agent              MIC/MBC (*μ*g/mL)   FIC/FBC      FICI/FBCI^2^   Outcome      
  -------------------- ------------------ ------------------- ------------ -------------- ------------ -----------------------------
  MSSA ATCC 25923^3^   Cryptotanshinone   64/256              16/64        0.25/0.25      0.5/0.5      **Synergistic/synergistic**
  Vancomycin           0.5/2              0.125/0.5           0.25/0.25                                
  MRSA ATCC 33591^4^   Cryptotanshinone   4/16                1/4          0.25/0.25      0.5/0.5      **Synergistic/synergistic**
  Vancomycin           1/4                0.25/1              0.25/0.25                                
  VRSA 3A063^5^        Cryptotanshinone   2/4                 0.5/1        0.125/0.25     0.375/0.5    **Synergistic/synergistic**
  Vancomycin           16/32              4/8                 0.25/0.25                                
  VRSA 3A066^6^        Cryptotanshinone   4/16                1/4          0.25/0.25      0.5/0.5      **Synergistic/synergistic**
  Vancomycin           32/64              8/16                0.25/0.25                                
  MSSA 1^7^            Cryptotanshinone   16/64               4/16         0.25/0.25      0.5/0.75     **Synergistic/additive**
  Vancomycin           1/4                0.25/2              0.25/0.5                                 
  MSSA 2               Cryptotanshinone   32/128              8/16         0.25/0.125     0.5/0.625    **Synergistic/additive**
  Vancomycin           1/2                0.25/1              0.25/0.5                                 
  MRSA 1^8^            Cryptotanshinone   16/32               4/8          0.25/0.25      0.5/0.5      **Synergistic/synergistic**
  Vancomycin           1/2                0.25/0.5            0.25/0.25                                
  MRSA 2               Cryptotanshinone   64/128              16/32        0.25/0.25      0.5/0.75     **Synergistic/additive**
  Vancomycin           2/4                0.5/2               0.25/0.5                                 
  MRSA 3               Cryptotanshinone   4/16                1/4          0.25/0.25      0.375/0.5    **Synergistic/synergistic**
  Vancomycin           2/4                0.25/1              0.125/0.25                               
  MRSA 4               Cryptotanshinone   4/8                 1/2          0.25/0.25      0.5/0.5      **Synergistic/synergistic**
  Vancomycin           1/2                0.25/0.5            0.25/0.25                                
  MRSA 5               Cryptotanshinone   64/128              16/32        0.25/0.25      0.5/0.5      **Synergistic/synergistic**
  Vancomycin           1/2                0.25/0.5            0.25/0.25                                
  MRSA 6               Cryptotanshinone   4/16                2/4          0.5/0.25       0.75/0.5     **Additive/synergistic**
  Vancomycin           1/2                0.25/0.5            0.25/0.25                                
  MRSA 7               Cryptotanshinone   8/16                2/4          0.25/0.25      0.5/0.375    **Synergistic/synergistic**
  Vancomycin           1/4                0.25/0.5            0.25/0.125                               
  MRSA 8               Cryptotanshinone   32/64               8/16         0.25/0.25      0.5/0.375    **Synergistic/synergistic**
  Vancomycin           1/4                0.25/0.5            0.25/0.125                               
  MRSA 9               Cryptotanshinone   8/16                2/4          0.25/0.25      0.5/0.5      **Synergistic/synergistic**
  Vancomycin           1/2                0.25/0.5            0.25/0.25                                
  MRSA 10              Cryptotanshinone   16/64               4/8          0.25/0.25      0.5/0.75     **Synergistic/additive**
  Vancomycin           1/2                0.25/1              0.25/0.5                                 
  MRSA 11              Cryptotanshinone   8/32                2/8          0.25/0.25      0.75/0.5     **Additive/synergistic**
  Vancomycin           1/2                0.5/0.5             0.5/0.25                                 
  MRSA 12              Cryptotanshinone   4/8                 1/2          0.25/0.25      0.5/0.375    **Synergistic/synergistic**
  Vancomycin           1/4                0.25/0.5            0.25/0.125                               
  MRSA 13              Cryptotanshinone   32/128              16/32        0.25/0.25      0.5/0.5      **Synergistic/synergistic**
  Vancomycin           1/2                0.25/0.5            0.25/0.25                                
  MRSA 14              Cryptotanshinone   8/16                2/4          0.25/0.25      0.5/0.5      **Synergistic/synergistic**
  Vancomycin           1/4                0.25/1              0.25/0.25                                
  MRSA 15              Cryptotanshinone   4/16                2/4          0.5/0.25       0.75/0.375   **Additive/synergistic**
  Vancomycin           1/4                0.25/0.5            0.25/0.125                               
  MRSA 16              Cryptotanshinone   8/16                2/4          0.25/0.25      0.375/0.5    **Synergistic/synergistic**
  Vancomycin           1/2                0.125/0.5           0.125/0.25                               

  ^1^The MIC and MBC of cryptotanshinone with vancomycin.

^2^The FIC index.

^3^MSSA (ATCC 25923): reference strain methicillin-sensitive *Staphylococcus aureus.*

^4^MRSA (ATCC 33591): reference strain methicillin-resistant *Staphylococcus aureus.*

^5^VRSA 3A063: vancomycin-resistant *Staphylococcus aureus* isolated clinically.

^6^VRSA 3A066: vancomycin-resistant *Staphylococcus aureus* isolated clinically.

^7^MSSA (1-2): methicillin-sensitive *Staphylococcus aureus* isolated clinically.

^8^MRSA (1--16): methicillin-resistant *Staphylococcus aureus*isolated clinically.

[^1]: Academic Editor: Tai-Long Pan
